Lipocine plunges after postpartum depression drug fails main goal in late-stage study

Shares of Lipocine LPCN.O plunge 77% to $2.10 premarket

The biotech firm says its experimental postpartum depression drug missed the main goal in a late‑stage study

Adds that oral drug LPCN 1154 did not significantly reduce depression scores versus placebo 60 hours after treatment in the full trial

In a smaller subgroup of patients with prior psychiatric history, drug showed quicker and longer‑lasting symptom improvement in a post‑hoc analysis - LPCN

Says drug was well tolerated with no serious side effects and no excess sedation or dizziness

Says it has sought FDA breakthrough therapy and fast‑track status and is weighing further studies or partnerships

Postpartum depression is a mood disorder that affects women after childbirth, causing persistent sadness, anxiety and difficulty bonding with the baby

As of last close, stock up ~15% YTD